Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Atopic Dermatitis
Sponsor: Regeneron Pharmaceuticals
Listed as NCT01385657, this PHASE1 trial focuses on Atopic Dermatitis and remains completed. Sponsored by Regeneron Pharmaceuticals, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE1
Phase: PHASE1_PHASE2 → PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Mar 2020 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regeneron Pharmaceuticals
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Auckland, New Zealand , Berlin, Germany , Bonn, Germany , Carlton, Australia , Caversham, New Zealand , Gera, Germany , Hanover, Germany , Kogarah, Australia , Münster, Germany , Nedlands, Australia and 2 more locations